These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 30340519

  • 21. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
    Sinha R, Roychoudhury J, Palit P, Ali N.
    Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
    [Abstract] [Full Text] [Related]

  • 22. Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.
    Singh-Phulgenda S, Dahal P, Ngu R, Maguire BJ, Hawryszkiewycz A, Rashan S, Brack M, Halleux CM, Alves F, Stepniewska K, Olliaro PL, Guerin PJ.
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009302. PubMed ID: 33780461
    [Abstract] [Full Text] [Related]

  • 23. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
    Mondal D, Kumar A, Sharma A, Ahmed MM, Hasnain MG, Alim A, Huda MM, Rahman R, Alvar J, Ahmed BN, Haque R.
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
    Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Alcoba G, Muthoni Ouattara G, Egondi T, Nakanwagi P, Omollo T, Wasunna M, Verrest L, Dorlo TPC, Musa Younis B, Nour A, Taha Ahmed Elmukashfi E, Ismail Omer Haroun A, Khalil EAG, Njenga S, Fikre H, Mekonnen T, Mersha D, Sisay K, Sagaki P, Alvar J, Solomos A, Alves F.
    Clin Infect Dis; 2023 Feb 08; 76(3):e1177-e1185. PubMed ID: 36164254
    [Abstract] [Full Text] [Related]

  • 26. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection.
    Hailu W, Weldegebreal T, Hurissa Z, Tafes H, Omollo R, Yifru S, Balasegaram M, Hailu A.
    Trans R Soc Trop Med Hyg; 2010 Nov 08; 104(11):706-12. PubMed ID: 20870258
    [Abstract] [Full Text] [Related]

  • 27. Leishmania donovani: genetic diversity of isolates from Sudan characterized by PCR-based RAPD.
    Hamad SH, Khalil EA, Musa AM, Ibrahim ME, Younis BM, Elfaki ME, El-Hassan AM, Leishmaniasis Research Group, Sudan.
    Exp Parasitol; 2010 Aug 08; 125(4):389-93. PubMed ID: 20346944
    [Abstract] [Full Text] [Related]

  • 28. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
    Thakur CP, Narayan S, Ranjan A.
    Indian J Med Res; 2004 Sep 08; 120(3):166-72. PubMed ID: 15489554
    [Abstract] [Full Text] [Related]

  • 29. A Comparison of the Effectiveness of Sodium Stibogluconate Monotherapy to Sodium Stibogluconate and Paromomycin Combination for the Treatment of Severe Post Kala Azar Dermal Leishmaniasis in South Sudan - A Retrospective Cohort Study.
    Abongomera C, Gatluak F, Buyze J, Ritmeijer K.
    PLoS One; 2016 Sep 08; 11(9):e0163047. PubMed ID: 27658288
    [Abstract] [Full Text] [Related]

  • 30. Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
    Mengstie TA, Endale HT, Mulaw T, Abdella AM, Mohammed R, Malik T, Dessie G.
    PLoS One; 2021 Sep 08; 16(10):e0257229. PubMed ID: 34597312
    [Abstract] [Full Text] [Related]

  • 31. Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in Northwest Ethiopia?
    Aderie EM, Diro E, Zachariah R, da Fonseca MS, Abongomera C, Dolamo BL, Ritmeijer K.
    Trans R Soc Trop Med Hyg; 2017 Mar 01; 111(3):107-116. PubMed ID: 28633331
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cytokine profiles, blood parasite load and clinical features of visceral leishmaniasis in West Pokot County, Kenya.
    van Dijk N, Carter J, Kiptanui D, Pinelli E, Schallig H.
    Parasitology; 2024 Jun 01; 151(7):753-761. PubMed ID: 39311405
    [Abstract] [Full Text] [Related]

  • 34. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK.
    Natl Med J India; 2005 Jun 01; 18(3):131-3. PubMed ID: 16130613
    [Abstract] [Full Text] [Related]

  • 35. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers.
    Solomon M, Pavlotzky F, Barzilai A, Schwartz E.
    J Am Acad Dermatol; 2013 Feb 01; 68(2):284-9. PubMed ID: 22858005
    [Abstract] [Full Text] [Related]

  • 36. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
    Oliva G, Foglia Manzillo V, Pagano A.
    Parassitologia; 2004 Jun 01; 46(1-2):231-4. PubMed ID: 15305724
    [Abstract] [Full Text] [Related]

  • 37. Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study.
    Perry MR, Prajapati VK, Menten J, Raab A, Feldmann J, Chakraborti D, Sundar S, Fairlamb AH, Boelaert M, Picado A.
    PLoS Negl Trop Dis; 2015 Mar 01; 9(3):e0003518. PubMed ID: 25730310
    [Abstract] [Full Text] [Related]

  • 38. The treatment of visceral leishmaniasis (kala-azar) in India: no obvious signs of long-term success.
    Muniaraj M, Paramasivan R, Mariappan T, Arunachalam N, Sinha PK.
    Trans R Soc Trop Med Hyg; 2012 Dec 01; 106(12):770-2. PubMed ID: 23102868
    [Abstract] [Full Text] [Related]

  • 39. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
    Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J, Leishmaniasis East Africa Platform (LEAP) group.
    PLoS Negl Trop Dis; 2010 Oct 26; 4(10):e709. PubMed ID: 21049059
    [Abstract] [Full Text] [Related]

  • 40. Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate.
    Salih MAM, Fakiola M, Lyons PA, Younis BM, Musa AM, Elhassan AM, Anderson D, Syn G, Ibrahim ME, Blackwell JM, Mohamed HS.
    Parasite Immunol; 2017 Jun 26; 39(6):. PubMed ID: 28370072
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.